Daily Stock Analysis, ACOR, Acorda Therapeutics Inc, priceseries

Acorda Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
30.65
Close
30.50
High
30.70
Low
30.10
Previous Close
30.55
Daily Price Gain
-0.05
YTD High
36.35
YTD High Date
Jun 8, 2018
YTD Low
20.50
YTD Low Date
Jan 5, 2018
YTD Price Change
7.85
YTD Gain
34.66%
52 Week High
36.35
52 Week High Date
Jun 8, 2018
52 Week Low
16.55
52 Week Low Date
Nov 16, 2017
52 Week Price Change
11.80
52 Week Gain
63.10%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
19.50
Jan 17. 2017
20.66
9 Trading Days
5.95%
Link
LONG
Feb 14. 2017
23.85
Mar 14. 2017
27.73
19 Trading Days
16.27%
Link
LONG
Jun 8. 2017
16.20
Jul 18. 2017
19.93
27 Trading Days
23.00%
Link
LONG
Sep 29. 2017
23.65
Oct 9. 2017
25.14
6 Trading Days
6.29%
Link
LONG
Jan 9. 2018
23.25
Jan 30. 2018
26.62
14 Trading Days
14.51%
Link
Company Information
Stock Symbol
ACOR
Exchange
NasdaqGS
Company URL
http://www.acorda.com
Company Phone
914-347-4300
CEO
Ronald Cohen
Headquarters
New York
Business Address
420 SAW MILL RIVER ROAD, ARDSLEY, NY 10502
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001008848
About

Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders. The company's two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. Acorda Therapeutics was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson's disease; SYN120, which is in Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.